154 related articles for article (PubMed ID: 3206137)
41. A treatment algorithm for autoimmune myasthenia gravis in childhood.
Andrews PI
Ann N Y Acad Sci; 1998 May; 841():789-802. PubMed ID: 9668332
[No Abstract] [Full Text] [Related]
42. [Myasthenia gravis--an autoimmune neuromuscular disease].
Pirskanen-Matell R; Matell G; Kalb B; Bjelak S
Lakartidningen; 2000 Oct; 97(41):4594-8. PubMed ID: 11107745
[No Abstract] [Full Text] [Related]
43. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
[TBL] [Abstract][Full Text] [Related]
44. Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis.
Bergamini L; Cocito D; Durelli L; Quattrocolo G
Muscle Nerve; 1983; 6(6):457-8. PubMed ID: 6621614
[No Abstract] [Full Text] [Related]
45. Myasthenia gravis: an unrecognized cause of head drop in Parkinson's disease.
Fasano A; Evoli A; Piano C; Tonali PA; Bentivoglio AR
Parkinsonism Relat Disord; 2008; 14(2):164-5. PubMed ID: 17459760
[TBL] [Abstract][Full Text] [Related]
46. [Myasthenia-like syndromes: current and future treatments].
Kuntzer T; Pedrazzi P
Praxis (Bern 1994); 1995 Sep; 84(38):1042-9. PubMed ID: 7481303
[TBL] [Abstract][Full Text] [Related]
47. Management of myasthenia gravis.
Lancet; 1982 Jul; 2(8290):135-6. PubMed ID: 6123843
[No Abstract] [Full Text] [Related]
48. [Myasthenia gravis; clinical aspects, pathophysiology and treatment].
Oosterhuis HJ
Ned Tijdschr Geneeskd; 1983 Sep; 127(39):1765-71. PubMed ID: 6314161
[No Abstract] [Full Text] [Related]
49. Plasma exchange therapy for severe penicillamine-induced myasthenia gravis.
Lang AE; Humphrey JG; Gordn DA
J Rheumatol; 1981; 8(2):303-7. PubMed ID: 7230162
[TBL] [Abstract][Full Text] [Related]
50. [Therapy of myasthenia gravis].
Rilling G; Tettenborn B
Praxis (Bern 1994); 2001 Aug; 90(33):1350-4. PubMed ID: 11534319
[TBL] [Abstract][Full Text] [Related]
51. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
52. Treating ocular Myasthenia Gravis with inadequate evidence.
Roach ES
Arch Neurol; 2007 Dec; 64(12):1794-5. PubMed ID: 18071049
[No Abstract] [Full Text] [Related]
53. Plasma exchange in myasthenia gravis.
Marconi G; Bobbi S; Pizzi A; Sbrilli C; Taiuti R; Ronchi O; Avanzi G; Lombardo R; Franco C; Biani D
Int J Artif Organs; 1984 Sep; 7(5):297-300. PubMed ID: 6500737
[TBL] [Abstract][Full Text] [Related]
54. The role of plasma exchange in treatment of myasthenia gravis.
Dau PC
Prog Clin Biol Res; 1982; 106():143-56. PubMed ID: 7178136
[No Abstract] [Full Text] [Related]
55. Thymoma, myasthenia gravis, and other paraneoplastic syndromes.
Tormoehlen LM; Pascuzzi RM
Hematol Oncol Clin North Am; 2008 Jun; 22(3):509-26. PubMed ID: 18514130
[TBL] [Abstract][Full Text] [Related]
56. Is myasthenia gravis an autoimmune disease?
Chriss JW
Tex Med; 1973 May; 69(5):72-4. PubMed ID: 4702315
[No Abstract] [Full Text] [Related]
57. Patient and family fact sheet. Myasthenia gravis: maximizing function.
Kernich CA
Neurologist; 2008 Jan; 14(1):75-6. PubMed ID: 18195664
[No Abstract] [Full Text] [Related]
58. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.
Benatar M; Sanders DB; Wolfe GI; McDermott MP; Tawil R
Ann N Y Acad Sci; 2012 Dec; 1275():17-22. PubMed ID: 23278573
[TBL] [Abstract][Full Text] [Related]
59. [Immuno suppressive drugs in the treatment of myasthenia (author's transl)].
Buscaino GA
Riv Patol Nerv Ment; 1974 Aug; 95(4):399-410. PubMed ID: 4377801
[No Abstract] [Full Text] [Related]
60. Early-onset myasthenia gravis: clinical characteristics and response to therapy.
Batocchi AP; Evoli A; Palmisani MT; Lo Monaco M; Bartoccioni M; Tonali P
Eur J Pediatr; 1990 Nov; 150(1):66-8. PubMed ID: 2079081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
